EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische Übersicht

Progressive familial intrahepatic cholestasis disease burden and clinical approaches: a systematic review

Simon P Horslen iD, Georg Vogel iD, Jolan Terner-Rosenthal iD, Nadav Zadok, Lorenzo D'Antiga iD

Journal of Comparative Effectiveness Research · 19.08.2026

DOI: 10.57264/cer-2026-0047 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Comparative Effectiveness Research, erschienen am 19.08.2026. Verfasst von Simon P Horslen und 4 weiteren Autor:innen. Beteiligte Einrichtung: UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA 15224, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 100 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Progressive familial intrahepatic cholestasis (PFIC) comprises a group of rare, heterogeneous genetic liver disorders characterized by impaired bile formation and cholestasis. Historically, treatment focused on supportive management and symptomatic relief, but disease-specific therapies, including ileal bile acid transporter inhibitors, have recently become available. This systematic review updates previous evidence on the epidemiology, natural history, psychosocial and economic burden of PFIC, and summarizes evidence on the efficacy, safety and cost-effectiveness of therapies used primarily in patients with PFIC type 2 (bile salt export pump [BSEP] deficiency). Materials & m ethods: Twenty-seven databases and supplementary literature sources were searched in February 2021 and updated in January 2025. Studies were selected to address five review questions. Due to substantial heterogeneity in study populations, PFIC subtypes, outcome definitions and study designs, findings were synthesized narratively.

Results

A total of 114 publications were included. Findings relating to epidemiology, natural history, psychosocial burden and economic burden were broadly consistent with previous reviews and highlighted the substantial impact of PFIC on children and their caregivers. Many patients treated with maralixibat and odevixibat demonstrated improvements in pruritus, serum bile acid concentrations, quality of life and markers of liver health, particularly those with PFIC2/BSEP deficiency. However, treatment responses varied across studies and genotypes, and long-term data remain limited. Only a small amount of economic evidence was identified.

Conclusion

PFIC is associated with significant clinical and psychosocial burden. Ileal bile acid transporter inhibitors provide a novel, targeted, nonsurgical treatment option for many patients: current evidence supports improvements in pruritus and serum bile acid control, particularly in PFIC2/BSEP deficiency; however, treatment responses are heterogeneous and additional long-term clinical and economic evidence is needed.

Schlagwörter

Stichwörter der Autor:innen

IBAT inhibitorsPFICcholestasishepatologyliverprogressive familial intrahepatic cholestasispruritussystematic literature review

Autor:innen und Institutionen

  • UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA 15224, USA.
  • University of Pittsburgh, Pittsburgh, PA 15261, USA.
  • Pediatrics I, Medical University of Innsbruck, Innsbruck, Austria.
  • Institute of Cell Biology, Medical University of Innsbruck, Innsbruck, Austria.
  • Mirum Pharmaceuticals, Inc. Foster City, CA 94404, USA.
  • Pediatric Hepatology, Gastroenterology & Transplantation, Hospital Papa Giovanni XXIII, Bergamo, Italy.

ORCID-Profile: Simon P Horslen, Georg Vogel, Jolan Terner-Rosenthal, Lorenzo D'Antiga

Zitieren

APA

Horslen, S. P., Vogel, G., Terner-Rosenthal, J., Zadok, N., & D'Antiga, L. (2026). Progressive familial intrahepatic cholestasis disease burden and clinical approaches: a systematic review. Journal of Comparative Effectiveness Research. https://doi.org/10.57264/cer-2026-0047

Vancouver

Horslen SP, Vogel G, Terner-Rosenthal J, Zadok N, D'Antiga L. Progressive familial intrahepatic cholestasis disease burden and clinical approaches: a systematic review. Journal of Comparative Effectiveness Research. 2026. doi:10.57264/cer-2026-0047

BibTeX
@article{Horslen2026,
  author = {Horslen, Simon P and Vogel, Georg and Terner-Rosenthal, Jolan and Zadok, Nadav and D'Antiga, Lorenzo},
  title = {Progressive familial intrahepatic cholestasis disease burden and clinical approaches: a systematic review},
  journal = {Journal of Comparative Effectiveness Research},
  year = {2026},
  doi = {10.57264/cer-2026-0047}
}
Kostenlos starten →